iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by Algert Global LLC

Algert Global LLC reduced its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 72.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,512 shares of the company’s stock after selling 186,627 shares during the quarter. Algert Global LLC owned approximately 0.19% of iTeos Therapeutics worth $534,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in ITOS. JPMorgan Chase & Co. increased its holdings in iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock valued at $15,888,000 after acquiring an additional 1,601,477 shares in the last quarter. Boxer Capital Management LLC purchased a new position in iTeos Therapeutics during the 4th quarter valued at about $7,272,000. Renaissance Technologies LLC increased its holdings in iTeos Therapeutics by 56.1% during the 4th quarter. Renaissance Technologies LLC now owns 837,200 shares of the company’s stock valued at $6,430,000 after acquiring an additional 300,800 shares in the last quarter. Almitas Capital LLC purchased a new position in iTeos Therapeutics during the 4th quarter valued at about $2,113,000. Finally, Eversept Partners LP purchased a new position in iTeos Therapeutics during the 4th quarter valued at about $1,691,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ITOS has been the subject of several recent research reports. JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th. Wells Fargo & Company lowered their price target on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $6.68 on Monday. The company has a market cap of $255.67 million, a PE ratio of -2.12 and a beta of 1.39. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.70. The company has a 50-day simple moving average of $6.55 and a 200-day simple moving average of $7.44.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14. On average, analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.